Description

Polapril (ramipril) hard capsules 5 mg. №28

Ingredients:

Each hard capsule contains 5 mg of ramipril as the active ingredient. Inactive ingredients include lactose monohydrate, pregelatinized starch, and gelatin.

Dosage:

The recommended dosage is one 5 mg capsule taken orally once daily. Dosage may vary based on individual patient needs and response to treatment.

Indications:

Polapril (ramipril) is indicated for the treatment of hypertension, heart failure, and to improve survival after a heart attack. It is also used to protect the kidneys in patients with diabetes.

Contraindications:

Do not use Polapril (ramipril) if you are pregnant, have a history of angioedema related to previous ACE inhibitor use, or have severe kidney disease. Consult your healthcare provider before starting this medication.

Directions:

Swallow the capsule whole with a glass of water. It can be taken with or without food, but consistency is key for optimal results.

Scientific Evidence:

Ramipril, the active ingredient in Polapril, is an ACE inhibitor that works by relaxing blood vessels, reducing the workload on the heart, and improving blood flow. Studies have shown that ramipril is effective in lowering blood pressure, reducing the risk of cardiovascular events, and improving outcomes in patients with heart failure.

Additional Information:

It is important to regularly monitor blood pressure and kidney function while taking Polapril (ramipril). Common side effects may include dizziness, cough, and low blood pressure. If you experience any severe side effects, contact your healthcare provider immediately.

Pharmacological Effects:

Ramipril inhibits the angiotensin-converting enzyme (ACE), leading to decreased production of angiotensin II, a potent vasoconstrictor. By blocking this enzyme, ramipril helps dilate blood vessels, reduce blood pressure, and improve cardiac function. Additionally, it can prevent the progression of heart failure and protect the kidneys in diabetic patients.

Clinical Trials and Comparative Effectiveness:

Clinical trials have demonstrated the efficacy of ramipril in reducing cardiovascular events and mortality in high-risk patients. In comparative studies, ramipril has shown similar or superior effectiveness compared to other ACE inhibitors in managing hypertension and heart failure. Its well-established safety profile and proven benefits make it a preferred choice in cardiovascular therapy.

References:

• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153.
• Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327(10):669-677.